Mode
Text Size
Log in / Sign up

Adjunctive ESWT after botulinum toxin type A improves motor scores in post-stroke spasticityShock wave therapy may improve movement after stroke injections

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider adjunctive ESWT after BTX-A for improved short-term motor scores, but note uncertain functional gains.

This systematic review and three-level meta-analysis evaluated the efficacy of adjunctive extracorporeal shock wave therapy (ESWT) following botulinum toxin type A (BTX-A) injections for adult post-stroke spasticity. The analysis included 377 participants qualitatively and 242 participants quantitatively. The authors synthesized data across three primary outcomes to determine the impact of the combined intervention compared to BTX-A-based comparators.

Key findings indicate a greater reduction in Modified Ashworth Scale scores (g = 0.87; 95% CI 0.41 to 1.34; p < 0.001) and greater improvement in Fugl-Meyer Assessment scores (g = 1.11; 95% CI 0.45 to 1.76; p < 0.001) for the combined therapy. While the combined intervention favored outcomes in Activities-of-daily-living (g = 1.15; 95% CI -0.03 to 2.32), this specific result did not reach conventional statistical significance (p = 0.056).

The authors note that certainty is limited and evidence for reliable functional independence gains is very uncertain. Specific findings regarding modality, target, timing, and dose remain exploratory. Clinically, adjunctive ESWT may improve short-term impairment-level outcomes after BTX-A, but its impact on long-term functional independence is not well-established.

How this fits prior evidence

This finding addresses a gap in the management of post-stroke spasticity by evaluating a specific adjunctive therapy. While previous evidence has explored robot-assisted training for lower-limb motor function and various brain-computer interface modalities for upper-limb rehabilitation, this meta-analysis specifically addresses the combination of ESWT and BTX-A. It provides evidence for short-term impairment-level improvements, though it does not provide data on the multimodal fusion technologies or airflow-restoration strategies mentioned in other stroke-related evidence.

Living with muscle stiffness, known as spasticity, after a stroke can make daily movements difficult and painful. A new review looked at what happens when patients receive a combination of two treatments: botulinum toxin type A injections and a technique called extracorporeal shock wave therapy (ESWT).

The analysis of 377 participants found that adding shock wave therapy to the injections led to a greater reduction in muscle stiffness scores. It also showed better improvements in overall movement scores. While the combined treatment trended toward helping patients with daily activities, this specific result did not reach a standard level of statistical certainty.

It is important to note that the evidence for long-term independence is still very uncertain. Because the study looked at many different types of shock waves and different timing, the results are still in the early stages of exploration. Two people experienced temporary skin redness after the shock wave treatment, but the overall safety data is currently incomplete.

What this means for you:
Adding shock wave therapy to botulinum injections may improve muscle stiffness and movement after a stroke.

Common questions

What is the benefit of adding shock wave therapy to injections?

Adding shock wave therapy to botulinum toxin type A injections showed a greater reduction in muscle stiffness scores compared to using injections alone. It also showed a greater improvement in movement scores for adults who experienced muscle stiffness after a stroke.

Does this treatment help with daily activities?

The combined treatment favored patients' ability to perform daily activities, but the results did not reach a standard level of statistical significance. Because of this, the evidence for reliable gains in functional independence is currently very uncertain.

Is the shock wave therapy safe for patients?

In the reported cases, two participants developed transient erythema, which is temporary skin redness, after the shock wave treatment. However, because the reporting was incomplete, a full comparison of safety between the different treatments is not yet available.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BackgroundPost-stroke spasticity is a common rehabilitation problem, and botulinum toxin type A (BTX-A) is a standard focal treatment. Whether extracorporeal shock wave therapy (ESWT) provides clinically relevant additional benefit after BTX-A remains uncertain.ObjectiveThis systematic review and three-level meta-analysis evaluated the add-on effect of ESWT after BTX-A for post-stroke spasticity, with particular attention to impairment-level and activities-of-daily-living outcomes. Methods: PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang Data, VIP, and CBM were searched from inception to March 2026. Randomized controlled trials of BTX-A plus ESWT in adult post-stroke spasticity were included. The primary quantitative synthesis was restricted to BTX-A-based comparators. Hedges' g was pooled with three-level random-effects models to account for dependent effect sizes.ResultsSeven randomized controlled trials with 377 participants met the qualitative criteria, and six trials with 242 participants contributed to the primary quantitative synthesis. Adjunctive ESWT was associated with greater reduction in Modified Ashworth Scale scores (g = 0.87, 95% CI 0.41 to 1.34; p < 0.001) and greater improvement in Fugl-Meyer Assessment scores (g = 1.11, 95% CI 0.45 to 1.76; p < 0.001). Activities-of-daily-living estimates favored the combined intervention but did not reach conventional statistical significance (g = 1.15, 95% CI −0.03 to 2.32; p = 0.056). Two participants developed transient erythema after ESWT, but adverse-event reporting was too incomplete for a comparative safety estimate.ConclusionAdjunctive ESWT may improve short-term impairment-level outcomes after BTX-A, but certainty is limited and evidence for reliable functional independence gains is very uncertain. Modality-, target-, timing-, and dose-specific findings remain exploratory.Systematic Review RegistrationIdentifier INPLASY202630010; https://doi.org/10.37766/inplasy2026.3.0010.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.